pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Humenza has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 30/06/2011

Authorisation details

Product details
Agency product number
Active substance
split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs.
International non-proprietary name (INN) or common name
pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)
Therapeutic area (MeSH)
  • Influenza, Human
  • Immunization
  • Disease Outbreaks
Anatomical therapeutic chemical (ATC) code
Conditional approvalConditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see Conditional marketing authorisation.

Publication details
Marketing-authorisation holder
Sanofi Pasteur S.A.
Date of issue of marketing authorisation valid throughout the European Union
Contact address

2, avenue Pont Pasteur
FR-69007 Lyon

Product information

14/06/2011 Humenza - EMEA/H/C/001202 - -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Prophylaxis of influenza in an officially declared pandemic situation.

Pandemic influenza vaccine should be used in accordance with Official Guidance.

Assessment history

Related content

How useful was this page?

Add your rating